A synthetic route that utilizes a cross-metathesis reaction with D 22 steroids has been developed to prepare sterols with varying C-27 side-chains. Natural sterols containing hydroxyl groups at the 25 and (25R)-26 positions were prepared. Enantiomers of cholesterol and (3b,25R)-26-hydroxycholesterol (27-hydroxycholesterol) trideuterated at C-19 were prepared for future biological studies.
Introduction
Side-chain oxysterols have been implicated in multiple important biological processes, including: bile acid synthesis [1] , cholesterol regulation and transport [2] [3] [4] [5] [6] , modulation of estrogen receptor function [7] , and apoptosis [8] . Further, these oxygenated cholesterol derivatives are believed to be significant in diseases such as Alzheimer's [9, 10] , Parkinson's [10, 11] , multiple sclerosis [10, 12] , Niemann-Pick type C disease [13] , and cataracts [14] . With regards to cholesterol homeostasis, (3b)-cholest-5-ene-3,25-diol (25-hydroxycholesterol, 25-HC, 1) and (3b,25R)-cholest-5-ene-3,26-diol (27-hydroxycholesterol, 27-HC, 3) are known to be modulators of sterol regulatory element binding proteins (SREBP), liver X receptors (LXR) and hydroxymethylglutaryl-coenzyme A (HMGCoA) reductase ( Fig. 1) [4] .
We are focused on the importance of the absolute configuration of 25-HC and 27-HC for their modes of action on cholesterol homeostatic-regulating proteins. We previously prepared the enantiomer of 25-HC (ent-25-HC) and have compared its biophysical and pharmacological properties with those of 25-HC [15] [16] [17] [18] . We are also interested in performing similar comparative activity studies with 27-HC and its enantiomer, ent-27-HC. Because ent-27-HC has not been prepared previously, we evaluated synthetic strategies for its preparation.
Generally, synthetic methods used for the total synthesis of a natural steroid can be used to make the corresponding ent-steroid simply by using a chiral starting material with the opposite absolute configuration of the natural steroid. Thus, for synthesizing ent-27-HC, methods used to synthesize 27-HC are relevant. 27 -HC has been prepared from the commercially available natural products diosgenin or kryptogenin [19] [20] [21] [22] . However, these synthetic methods are not useful for preparing ent-27-HC because neither ent-diosgenin nor ent-kyptogenin occurs naturally and it is impractical to first prepare either of them for subsequent conversion into ent-27-HC.
A literature precedent for the synthesis of 27-HC from (3b)-hydroxychol-5-en-24-oic acid has been reported [23] . We have previously reported the total synthesis of ent-lithocholic acid [24] and we could have modified this synthesis to prepare the enantiomer of (3b)-3-hydroxychol-5-en-24-oic acid, then converted it to ent-27-HC. While this route could have enabled the total synthesis of ent-27-HC, we also sought a method that could prepare a variety of side-chains on the steroid. Therefore, we modified our ent-lithocholic acid synthesis to prepare an ent-D 22 steroid which allowed us to utilize a cross-metathesis reaction with either 2 nd generation Grubbs catalyst or Stewart-Grubbs catalyst to install the remaining portions of the side-chain and complete the synthesis of ent-27-HC. We used this synthetic approach to prepare ent-27-HC-d 3 (5) . We also demonstrated the generality of this approach for making side chain modified sterols by preparing 25-HC (1), 25-HC-d 6 , (2), 27-HC (3) and ent-cholesterol-d 3 (entChol-d 3 , 4). The deuterated ent-sterols 4 and 5 will be of utility in future biological studies.
Experimental

General methods
Solvents were either used as purchased or dried and purified by standard methods. All air and/or moisture sensitive reactions were carried out under nitrogen environments using oven-dried glassware, which was cooled under nitrogen gas. Flash chromatography was performed using silica gel (32-63 lm) purchased from Scientific Adsorbants (Atlanta, GA). Optical rotations were determined at room temperature on a Perkin-Elmer Model 341 polarimeter. Melting points were determined utilizing a Kofler micro hot stage and are uncorrected. IR spectra were recorded on a NaCl plate with a Perkin-Elmer 1710 FT-IR spectrophotometer. NMR spectra were recorded at ambient temperature in CDCl 3 with a 5 mm probe on a Varian Gemini 2000 operating at 300 MHz (  1 H) or 75 MHz (  13 C) and were referenced to CDCl 3 (7.27 ppm or 77.00 ppm, respectively). Elemental analyses were performed by M-H-W laboratories (Phoenix, AZ). Lithocholic acid was purchased from Steraloids, Newport, RI, USA. (20 mL) . NaI (530 mg) was added, N 2 was bubbled through the solution for 30 min, and then the reaction was cooled to 0°C. SiMe 3 Cl (0.4 mL) was added dropwise and the reaction was stirred at 0°C under N 2 for 30 min, then at room temperature for 3 h. The acetic anhydride was removed in vacuo and satd. aqueous NaHCO 3 was added to the resulting residue. The product was extracted into EtOAc (3 Â 40 mL) and the combined extracts were 
Compound 5 (65 mg, 60%) was prepared from compound 36 (120 mg, 0.261 mmol) using the three step procedure described for the preparation of compound 3. 
(3a,5b)-24-norchol-22-en-3-ol (10)
(3a,5b)-24-Norchol-22-en-3-ol, 3-acetate (6, 6.17 g, 16.56 mmol, 1 eq) prepared according to the literature [25] , was dissolved in hot MeOH (300 mL) and benzene (50 mL). K 2 CO 3 (10.3 g, 74.5 mmol, 4.5 eq) was added and the mixture was heated to reflux and stirred overnight. The solvent was removed in vacuo and 1 M HCl was added. The product was extracted into CH 2 
(3a,5b)-3-Hydroxychol-22-en-24-oic acid, methyl ester (11)
Compound 10 (2.52 g, 7.62 mmol) was dissolved in CH 2 Cl 2 (200 mL), trans-3-hexenedioic acid dimethyl ester (1.2 mL, 7.67 mmol) and Grubbs catalyst, 2nd generation (660 mg, 0.78 mmol) were added. The reaction was heated to reflux and allowed to stir for 40 h. CH 2 Cl 2 was removed in vacuo and the product was partially purified by flash column chromatography (silica gel eluted with hexanes:EtOAc, 6:1 to 4:1) to recover a mixture of cis/trans isomers to give compound 11 (2.17 g) as a light brown solid which was converted to compound 12 without further purification or characterization.
(3a,5b)-3-Hydroxycholane-24-carboxylic acid, methyl ester (12)
Compound 11 (2.01 g, 4.99 mmol) was dissolved in EtOAc (150 mL) and Pd/C (1.0 g, 10% on charcoal) was added to a round-bottomed flask equipped with a balloon and evacuated and purged with H 2 (3x). The reaction was stirred while bubbling H 2 through the solvent for 3 h. The solution was filtered through celite and the solvent removed in vacuo to yield compound 11 (2.01 g, 70%, 2 steps from compound 
(5b)-3-Oxocholane-24-carboxylic acid, methyl ester (13)
Compound 12 (2.01 g) was dissolved in acetone (250 mL) and N 2 was bubbled through the solution for 30 min. Jones reagent (30% H 2 SO 4 , 30% chromic acid) was added dropwise until a persistent yellow color remained. The reaction was allowed to stir at room temperature under N 2 for 2 h. Water was added and the acetone removed in vacuo. Brine (100 mL) was added and the product was extracted into EtOAc (3 Â 250 mL). The combined extracts were washed with brine (200 mL), dried over anhydrous Na 2 SO 4 and the solvents removed under reduced pressure. The product was purified by flash column chromatography (silica gel eluted with hexanes:EtOAc, 9:1) to obtain compound 13 ( 
3-Oxochol-4-ene-24-carboxylic acid, methyl ester (14)
Compound 13 (110 mg, 0.273 mmol) was dissolved in AcOH (50 mL) and pyridinium tribromide (102 mg, 0.319 mmol) was added. The mixture was stirred, under N 2 at room temperature for 1 h. The AcOH was removed in vacuo and satd. aqueous NaHCO 3 was added to the residue. The product was extracted into EtOAc (3 Â 40 mL), dried over anhydrous Na 2 SO 4 and the solvents removed under reduced pressure. The brominated intermediate was partially purified by flash column chromatography (silica gel eluted with hexanes:EtOAc, 6:1). The partially purified intermediate was dissolved in DMF (40 mL) and LiCl (450 mg, 10.62 mmol) was added. The solution was heated to 100°C and stirred for 2 h under N 2 . DMF was removed in vacuo and 1 M HCl (50 mL) was added. The product was extracted into EtOAc (3 Â 40 mL) and the combined extracts dried over anhydrous Na 2 
(2R,7R)-2,7-dimethyl-oct-4-ene-1,8-diol (18)
Partially purified compound 17 (4.45 g, 8.58 mmol) was dissolved in dry THF and cooled to 0°C while stirring under N 2 . LiAlH 4 (55 mL, 2 M in THF) was added and the reaction was allowed to reach room temperature and stirred overnight. The LiAlH 4 was quenched by sequentially adding water (4.2 mL), 8.4 mL 10% NaOH (8.4 mL) and 12.6 mL water (12.6 mL). Precipitates were removed by filtration and the product extracted into EtOAc (3 x 200 mL). The combined extracts were washed with brine, dried over anhydrous Na 2 SO 4 and the solvents removed under reduced pressure. The product was partially purified by flash column chromatography (silica gel eluted with hexanes:EtOAc, 2:1) to obtain compound 18 (1.4 g, 65%) as a mixture of E and Z isomers which was used directly in the Grubbs cross-metathesis reaction with compound 19.
(5b)-24-Norchol-22-en-3-one (19)
Compound 19 (1.37 g, 93%) was prepared from compound 6 (1.49 g, 4.51 mmol) using the procedure described for the preparation of compound 13. 
(5b,25R)-26-(Acetyloxy)-cholestan-3-one (21)
Compound 20 (170 mg, 0.420 mmol) was dissolved in pyridine (30 mL). Acetic anhydride (0.6 mL, 6.35 mmol) and 4-(dimethylamino)pyridine (20 mg, 0.16 mmol) were added and the mixture stirred under N 2 at room temperature for 3.5 h. The pyridine was removed in vacuo. Water was poured over the residue and the product extracted into EtOAc (3 Â 40 mL). The combined extracts were washed with brine, dried over anhydrous Na 2 SO 4 
(25R)-26-(Acetyloxy)-cholest-4-en-3-one (22)
Compound 22 (74 mg, 51%) was prepared from compound 21 (146 mg, 0.323 mmol) using the procedure described for the preparation of compound 14. 
2,7-dimethyloct-4-ene (24)
4-Methyl-1-pentene (20 mL, 157.8 mmol) was dissolved in CH 2 Cl 2 . Grubbs catalyst, 2nd generation (189 mg, 0.23 mmol) was added and the reaction was stirred under N 2 at room temperature for 12 h. The product was purified by flash column chromatography (silica gel eluted with hexanes) to obtain compound 24 as an oil (5.7 g, 51%): 1 
(2S,7S)-2,7-bis(methyl)-1,8-bis[(4R)-2-oxo-4-(phenylmethyl)-3-oxazolidinyl]-4-octene-1,8-dione (26)
Compound 25 (5.02 g, 21.5 mmol) was dissolved in CH 2 Cl 2 (250 mL) and Grubbs catalyst, 1st generation (1.5 g, 1.8 mmol) was added. The reaction was heated to reflux and stirred under N 2 for 40 h. The CH 2 Cl 2 was removed in vacuo and the product partially purified by flash column chromatography (silica gel eluted with hexanes:EtOAc, 4:1 to 2:1) to obtain compound 26 (3.94 g, 83%) as a gray solid, which was not characterized before being converted to compound 27.
(2S,7S)-2,7-dimethyl-oct-4-ene-1,8-diol (27)
Compound 27 (1.13 g, 82%) was prepared from compound 26 (3.94 g, 8.03 mmol) using the procedure described for the prepara-tion of compound 18. Compound 27 was not characterized before being converted to compound 28.
(2S,7S)-2,7-dimethyl-4-octene-1,8-diol, diacetate (28)
Compound 28 (1.11 g, 66%) was prepared from compound 27 (1.13 g, 6.56 mmol) using the procedure described for the preparation of compound 21. [24] , then dissolved in dry THF and cooled to À78°C. DIBAL-H (1.5 M in THF, 25 mL) was added and the reaction was stirred under N 2 at À78°C for 1 h. Sodium potassium tartrate was added slowly until bubbling ceased. The product was extracted into EtOAc (2 Â 250 mL), then washed with brine (100 mL), dried over anhydrous Na 2 SO 4 and the solvents removed under reduced pressure. The product was purified by flash column chromatography (silica gel eluted with hexanes:EtOAc 
ent-[(3a,5b)-Cholesta-16,22-diene-19,19,19-d 3 -3-ol](31)
Compound 30 (780 mg, 2.08 mmol) was dissolved in CH 2 Cl 2 (300 mL) and compound 24 (945 mg, 6.74 mmol) was added, followed by the addition of 1,3-bis(2-methylphenyl)-2-imidazolidinylidene]dichloro(2-isopropoxyphenylmethylene)ruthenium (II) (478 mg, 0.84 mmol). The reaction was heated to reflux and stirred under N 2 for 72 h. The solvent was removed in vacuo and the product partially purified by flash column chromatography (silica gel eluted with hexanes:EtOAc, 9:1 to 2:1) to obtain semipurified compound 31 (630 mg, 78%) which was not characterized before being converted to compound 33. Partially purified compound 32 (630 mg, 63%) was prepared from compound 30 (840 mg, 2.24 mmol) and compound 28 (650 mg, 2.53 mmol) using the procedure described for the preparation of compound 31. The product was not characterized before being converted to compound 34.
ent-[(5b)-cholestan-3-one-19,19,19-d 3 ] (33)
Compound 31 (630 mg, 1.63 mmol) was dissolved in EtOAc (150 mL) and hydrogenated (70 psi) using 10% Pd/C (414 mg) as catalyst. The hydrogenation was run overnight. The product was filtered through celite, and the solvent removed in vacuo. This product was dissolved in acetone, and Jones reagent added until a persistent yellow color was achieved. This reaction was stirred under N 2 for 30 min, brine was added and the product extracted into EtOAc (3 Â 100 mL). The combined extracts were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 and the solvents removed under reduced pressure. 
Results and discussion
Our goal was to develop a synthetic route that could be utilized to synthesize a variety of side-chain oxysterols in both the natural and unnatural (ent) sterol series. We chose to start with either lithocholic acid or ent-lithocholic acid as starting materials; the former is commercially available and the latter was previously synthesized [24] . The synthetic strategy was to convert these steroid enantiomers to their corresponding D 22 steroids and subsequently utilize a cross-metathesis reaction to convert them to our target steroids (Fig. 1 ). Methods were first developed in the natural steroid series because of its ready availability. In order to generate the D 22 -steroid for the Grubbs crossmetathesis, lithocholic acid was acetylated at the 3-position and then subjected to oxidative decarboxylation using Pb(OAc) 4 , Cu (OAc) 2 and catalytic pyridine to obtain steroid 6 as described previously [25] . A series of reactions were attempted to crossmetathesize steroid 6 with 2-methylpent-4-en-2-ol (7, synthesized as previously described [27] ), using Grubbs catalyst, 2nd Generation (Scheme 1). Unfortunately, the yields for steroid 8 (characterized only by 1 H NMR) were poor (31-39%), despite attempts to Scheme 1. Attempts to cross-metathesize the Doptimize this reaction with varying solvent conditions, temperature, reaction time and equivalents of either olefin 7 or the Grubbs catalyst. In all attempts, the main product was homo-metathesized olefin 9 (previously prepared by other methods [28] ) and unreacted steroid 6. This is consistent with a recent report attempting similar cross-metathesis reactions on D 22 -steroids [29] . However, we found that if olefin 9 was used in place of olefin 7, the crossmetathesis with the D 22 -steroid proceeded smoothly. The high reactivity of terminal olefin 7 with the catalyst apparently resulted in the exhaustion of the catalytic cycle prior to involvement of 6. We conclude that the less reactive internal olefins perform better than terminal olefins in cross-metathesis reactions with D 22 -steroids.
In order to generate 25-HC (1) and 25-HC-d 6 (2), steroid 6 was deacetylated (higher yields were obtained with the deacetylated steroid) with K 2 CO 3 to obtain steroid 10 in 87% yield (Scheme 2). Steroid 10 was then treated with trans-3-hexenedioic acid dimethyl ester and Grubbs catalyst, 2nd generation to form the crossmetathesis product 11 as a mixture of E and Z isomers (E:Z ratio >95:5), which upon hydrogenation generated steroid 12 in good yield (70%, 2 steps). Steroid 12 was then oxidized to the 3-ketosteroid 13 using Jones reagent (96%). The 4-position of steroid 13 was selectively brominated using pyridinium tribromide in HOAc and subsequently converted with LiCl in DMF to the known D 4 -3-ketosteroid 14 [30] The synthetic route utilized for the ent-steroids was very similar to that described for the natural steroids. The reagent used to generate the side-chain for ent-Chol-d 3 (4) in the cross-metathesis reaction was synthesized by treating 4-methylpent-1-ene with Grubbs catalyst, 1 st generation to obtain 2,7-dimethyloct-4-ene 24 as a mixture of E and Z isomers in 51% yield (Scheme 5). The side-chain used to construct ent-27-HC-d 3 (5) was synthesized similarly to that for 27-HC. (4R)-3-(1-oxopropyl)-4-(phenylmethyl)-2-oxazolidinone was allylated, treated with 1st generation Grubbs catalyst to generate the disubstituted olefin, and hydrolyzed to synthesize the diol 27. This compound was then acetylated with acetic anhydride, DMAP, and pyridine to generate the bis-acetylated product 28 in 50% overall yield for the four steps.
ent-Testosterone-19,19,19-d 3 was synthesized as previously reported [32] . The deuterium labeled ent-testosterone was then converted to ent-steroid 29 (Scheme 6) in the same manner that unlabeled ent-testosterone was converted to the analogous unlabeled steroid [24] . In order to simplify the synthesis, we attempted to perform the cross-metathesis reaction directly on the natural enantiomer of compound 29 using both 2nd generation Grubbs catalyst and the more active ruthenium catalyst, 38. This simplification was unsuccessful; however, when the natural enantiomer of compound 29 was reduced to the natural enantiomer of compound 30 using DIBAL-H, we found that the ruthenium-based catalyst 38 successfully catalyzed its cross-metathesis reaction with olefin 24. Therefore, ent-steroid 29 was reduced to ent-steroid 30 with DIBAL-H (97%) and was then treated with the ruthenium-based catalyst 38 and either olefin 24 or 28 to form ent-steroids 31 or 32, respectively. Both ent-steroids were then hydrogenated and oxidized with Jones reagent to generate ent-steroids 33 and 34 in 54% and 35% yield, respectively over 3 steps. Treatment of ent-steroids 33 and 34 with pyridinium tribromide in HOAc followed by LiCl in DMF yielded ent-steroids 35 and 36 in 45% and 42% yield, respectively. These D 4 -3-ketones were then converted either to ent-Chol-d 3 (65%) or to the acetylated intermediate 37 as described for the preparation of steroid 15. Treatment of ent-steroid 37 with K 2 CO 3 yielded ent-27-HC-d 3 in 60% yield from ent-steroid 35. entChol-d 3 has previously been prepared by a different total synthesis method [33] .
In summary, a cross-metathesis reaction has been successfully utilized to synthesize 25-HC (1), 25-HC-d 6 (2), 27-HC (3), entChol-d 3 (4) and ent-27-HC-d 3 (5) . We believe the methodology developed will be of general use for synthesizing other analogues with side-chains that are different from those described here. Further studies utilizing the newly synthesized ent-27-HC-d 6 to probe the mechanism for its regulation of cholesterol homeostasis are anticipated.
